Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Pliant Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
PLRX
Nasdaq
2834
https://pliantrx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Pliant Therapeutics Inc
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
- Mar 27th, 2024 2:23 pm
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
- Mar 12th, 2024 11:30 am
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
- Mar 7th, 2024 3:00 pm
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
- Feb 27th, 2024 9:03 pm
Pliant Therapeutics to Participate in Upcoming Investor Conferences
- Feb 26th, 2024 1:00 pm
Pliant Therapeutics to Participate in Upcoming Investor Events
- Feb 7th, 2024 1:00 pm
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
- Feb 4th, 2024 8:29 pm
Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares
- Jan 20th, 2024 1:28 am
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 1:00 pm
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
- Nov 13th, 2023 9:30 pm
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Nov 9th, 2023 9:05 pm
Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?
- Nov 9th, 2023 1:44 pm
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- Nov 7th, 2023 3:00 pm
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
- Nov 6th, 2023 1:00 pm
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
- Oct 31st, 2023 8:03 pm
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
- Oct 19th, 2023 12:00 pm
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
- Oct 16th, 2023 8:05 pm
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
- Sep 28th, 2023 1:58 pm
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
- Sep 27th, 2023 2:52 pm
Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock?
- Sep 27th, 2023 1:01 pm
Scroll